Nasdaq - Delayed Quote USD

Janus Henderson Global Life Sciences T (JAGLX)

73.86 -0.28 (-0.38%)
As of 8:06 AM EDT. Market Open.

Top 10 Holdings (38.01% of Total Assets)

SymbolCompany% Assets
LLY
Eli Lilly and Company 7.06%
UNH
UnitedHealth Group Incorporated 5.85%
NOVO-B.CO
Novo Nordisk A/S 5.18%
MRK
Merck & Co., Inc. 3.63%
AZN.L
AstraZeneca PLC 3.57%
ABBV
AbbVie Inc. 3.36%
SAN.PA
Sanofi 2.49%
BSX
Boston Scientific Corporation 2.31%
VRTX
Vertex Pharmaceuticals Incorporated 2.30%
ABT
Abbott Laboratories 2.27%

Sector Weightings

SectorJAGLX
Healthcare   100.00%
Real Estate   0.00%
Technology   0.00%
Utilities   0.00%
Industrials   0.00%
Energy   0.00%

Overall Portfolio Composition (%)

Cash 0.77%
Stocks 98.02%
Bonds 0.00%
Others 0.89%
Preferred 0.27%
Convertible 0.05%

Bond Ratings

US Government 0.00%
AAA --
AA --
A --
BBB --
BB --
B --
Below B --
Other --

Equity Holdings

Average JAGLX Category Average
Price/Earnings 0.03 24.55
Price/Book 0.19 5.28
Price/Sales 0.39 2.06
Price/Cashflow 0.05 17.54
Median Market Cap 62,641.07 34,862.81
3 Year Earnings Growth 2.67 32.48

Bond Holdings

Performance & Risk

YTD Return 7.48%
5y Average Return 12.01%
Rank in Category (ytd) 19
% Rank in Category (ytd) --
Beta (5Y Monthly) 0.74
Morningstar Risk Rating

Fund Overview

Category Health
Fund Family Janus Henderson
Net Assets 5.1B
YTD Return 3.48%
Yield 0.07%
Morningstar Rating
Inception Date Dec 31, 1998

Fund Summary

The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio management believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.

Related Tickers